Biogen: stock soars on positive Alzheimer results

(CercleFinance.com) - Biogen shares have soared over 35% in early trading on Wednesday on the Nasdaq after the US biotech company announced positive results from a clinical trial in a drug against Alzheimer's disease.


Biogen and its Japanese partner Eisai last night unveiled findings from a trial of lecanemab (BAN2401), an investigational antibody they are targeting for the treatment of moderate cognitive impairment in the neurodegenerative disease.

The laboratories point out that lecanemab met its primary endpoint, which was a measure of dementia symptoms, as well as all of its secondary endpoints, with "highly significant" results, they say.

Wells Fargo analysts, said the results are much clearer than expected.



Copyright (c) 2022 CercleFinance.com. All rights reserved.